Peter Van Veldhuizen, MD, Oncology, Rochester, NY

PeterJayVan VeldhuizenMD

Oncology Rochester, NY

Genitourinary Oncology, Hematologic Oncology

Director of Genitourinary Medical Oncology, University of Rochester Medical Center

Dr. Van Veldhuizen is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Van Veldhuizen's full profile

Already have an account?

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineFellowship, Medical Oncology, 1989 - 1992
  • University of Kansas School of Medicine
    University of Kansas School of MedicineResidency, Internal Medicine, 1986 - 1989
  • Sanford School of Medicine of the University of South Dakota
    Sanford School of Medicine of the University of South DakotaClass of 1986
  • University of South DakotaB.S., Chemistry, Cum Laude, 1979 - 1982
  • South Dakota School of Mines and TechnologyNo degree, 1978 - 1979

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2020 - 2022
  • MO State Medical License
    MO State Medical License 2016 - 2022
  • KS State Medical License
    KS State Medical License 1988 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Super Doctors 2014
  • VA Lifetime Achievement Award 2011
  • Best Doctor Best Doctors of America, 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...  
    Goldkorn A, Ely B, Tangen CM, Tai Y, Xu T, Hongli Li, Twardowski P, Van Veldhuizen PJ, Neeraj Agarwal N, Carducci MA, Monk III JP, Garzotto M, Mack PC, Lara Jr. P, Hig..., Journal of Clinical Oncology, 1/10/2013
  • Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy  
    Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators, Eur J Cancer, 1/1/2013
  • Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer  
    Dubey S, Gunewardena S, Van Veldhuizen P, Thrasher JB, Karan D, Journal for Immunotherapy of Cancer, 1/1/2013
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • In vitro efficacy of MAGMAS inhibition in prostate cancer
    Das BC, Powers BC, Bouzahzah B, Borrego-Diaz E, Van Veldhuizen PJ, ASCO; Genitourinary Cancers Symposium, 1/30/2014
  • Applicability of MIC-1 as a potential biomarker for racial disparity in prostate cancer
    Dubey S, Wick J, Tawfik, O, Zainfeld D, Holzbeierlein J, Van Veldhuizen P, Thrasher JB, Karan D, AUA Annual Meeting, Orlando, FL, 1/16/2014
  • MAGMAS inhibition in hepatocellular carcinoma
    Das BC, Powers BC, Bouzahzah B, Borrego-Diaz E, Van Veldhuizen PJ, 248th ACS National Meeting, 1/10/2014
  • Join now to see all